- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Monopar Therapeutics, having taken over sponsorship of ALXN1840 from Alexion, is enrolling in clinical trials and must comply with federal regulations.
Monopar Therapeutics submitted a New Drug Application (NDA) to the FDA for review.
1 report, 1 independent
Updated Jul 22
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Monopar Therapeutics submitted a New Drug Application (NDA) to the FDA for review.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Monopar Therapeutics
biopharmaceutical company
Nothing else this week.
Related events
- FDA approval supports NDA submission in Aurora.
- BridgeBio announced on August 14, 2026, that it has submitted New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA).
- Novoheart, a subsidiary of Medera Inc., is collaborating with Mayo Clinic on mini-heart models, aligning with FDA guidelines for drug development.